Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
tacedinaline · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| gemcitabine hydrochloride | DRUG | - |
| tacedinaline | DRUG | - |
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed recurrent, locally advanced, or metastatic, unresectable non-small cell lung cancer Failed or relapsed after one prior platinum containing regimen (cisplatin or carboplatin) as first line therapy Prior brain metastases allowed if res...
Top 20 of 76 competitors
Tacedinaline is an investigational small molecule being studied for the treatment of lung cancer and pancreatic cancer. It is being developed by Pfizer, Inc. (NYSE: PFE). The drug is in clinical development and is not approved by the FDA.
Tacedinaline is a small molecule that was studied in combination with gemcitabine for advanced non-small cell lung cancer and advanced pancreatic cancer. Its specific molecular target is not disclosed in the available information.
Tacedinaline is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule for oncology indications.
Tacedinaline has been studied in clinical trials, including a Phase 3 trial for advanced non-small cell lung cancer. It remains investigational and is not FDA approved. The drug is not currently in active clinical trials.
Tacedinaline has been evaluated in two completed clinical trials. NCT00004861 studied gemcitabine with or without tacedinaline in advanced pancreatic cancer. NCT00005093 studied gemcitabine with or without tacedinaline in advanced non-small cell lung cancer.
Yes, tacedinaline is also known as CI-994. Clinical trials for the drug used the name CI-994 in their titles, such as NCT00005093 for lung cancer and NCT00004861 for pancreatic cancer.